Havrix, 720 units 0.5 ml
€1.00
Out of stock
(E-mail when Stock is available)
Havrix provides active immunity against hepatitis A virus for at least 15-20 years (when using a two-dose vaccination schedule).
In clinical researches it was found that antibodies to hepatitis A antigen on the 15th day after vaccination in persons 18-50 years old are formed in 88% of cases, 1-18 years old – in 93% of cases; one month after vaccination – in 99% of cases in both age groups. Vaccine use is effective in the early incubation period of the disease.
The effectiveness of the vaccine is not reduced in the presence of maternal antibodies to hepatitis A virus or antibodies to hepatitis A virus introduced passively in the blood of the vaccinated person.
Indications
Active immunoprophylaxis for hepatitis A.
Active ingredient
Composition
1 dose of suspension for injection for children contains:
the active ingredient:
Hepatitis A virus antigen 720 units (determination by enzyme-linked immunosorbent assay, ELISA)
How to take, the dosage
Havrix is administered intramuscularly.
In children from 1 year old and adolescents up to and including 18 years old: 720 IU (0.5 ml) in the anterolateral region of the thigh or deltoid muscle.
A 6 to 12 months after the first vaccination it is recommended that it be repeated.
Patients with thrombocytopenia or clotting disorders are injected subcutaneously.
Interaction
Mixing with other vaccines in the same syringe is not allowed.
Compatible with all vaccines in the Russian National Vaccine Calendar and all travel vaccines.
Special Instructions
If Xavrix is administered simultaneously with other vaccines, injections should be given at different sites.
In patients on hemodialysis and those with severe immunodeficiency, antibody formation to the hepatitis A antigen after a single dose of vaccine may be insufficient, so additional doses are recommended for these patients.
Contraindications
Hypersensitivity to any of the components of the vaccine.
Open and chronic inflammatory diseases with fever (vaccination is postponed until the body temperature returns to normal).
Side effects
Local:~ 4% of cases – swelling, redness at the injection site;
Systemic: 0.8-12.8% of cases – headache, malaise, nausea, vomiting, loss of appetite (no treatment, lasts less than 24 hours).
Pregnancy use
Only if absolutely necessary.
Weight | 0.020 kg |
---|---|
Shelf life | 3 years |
Conditions of storage | At 2-8 °C (do not freeze) |
Manufacturer | GlaxoSmithKlein Bayolodgicals s.a., Belgium |
Medication form | suspension |
Brand | GlaxoSmithKlein Bayolodgicals s.a. |
Related products
Buy Havrix, 720 units 0.5 ml with delivery to USA, UK, Europe and over 120 other countries.